Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|October 16, 2012
Twitter feed Psychiatric Times Coverage of HMP Global, LLC’s Psych Congress® Conference 2012
Listen
0:00 / 0:00
Key Takeaways
- Source material is derived from Psych Congress® presentations and then shaped into articles and interviews by Psychiatric Times editors and contributors.
- Independence is emphasized through clear statements of no affiliation, endorsement, or sponsorship by third parties.
Advertisement
The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
2
The Psychiatric Pipeline in Review: Quarter 3, 2026
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
5